Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May 10;7(6):332-42.
doi: 10.1038/nrneurol.2011.61.

Risk factors for and management of cognitive dysfunction in multiple sclerosis

Affiliations
Review

Risk factors for and management of cognitive dysfunction in multiple sclerosis

Ralph H B Benedict et al. Nat Rev Neurol. .

Abstract

Cognitive impairment is common in multiple sclerosis (MS), especially when assessed by neuropsychological tests that emphasize mental processing speed, episodic memory, and some aspects of executive function. In this Review, we question why some MS patients develop severe impairment in cognitive abilities, while cognitive ability remains intact in others. We find that the heterogeneity in neuropsychological presentation among patients with MS reflects the influence of many factors, including genetics, sex, intelligence, disease course, comorbid neuropsychiatric illness, and health behaviors. Neuropsychological deficits are also robustly correlated with brain MRI metrics. Male patients with early evidence of cerebral gray matter atrophy are most prone to impairment, whereas high premorbid intelligence improves the neuropsychological prognosis. Routine evaluation of cognition is useful for helping patients to navigate problems related to activities of daily living and work disability and, if reliable methods are employed, cognitive decline can be detected and included among the many clinical signs of disease progression or treatment failure. Pharmacological treatments for neuropsychological impairment are on the horizon, although presently no firm medical indications exist for the condition.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Neurology. 2004 Jul 13;63(1):89-93 - PubMed
    1. Neurology. 1991 May;41(5):692-6 - PubMed
    1. J Clin Exp Neuropsychol. 1998 Jun;20(3):376-90 - PubMed
    1. Int J Neurol. 1968;7(1):44-54 - PubMed
    1. Neurology. 1998 Jun;50(6):1609-17 - PubMed

Substances